- Home
- RFI vs FHTX Comparison
RFI vs FHTX Comparison
Compare RFI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- FHTX
- Stock Information
- Founded
- RFI 1992
- FHTX 2015
- Country
- RFI United States
- FHTX United States
- Employees
- RFI N/A
- FHTX N/A
- Industry
- RFI Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- RFI Finance
- FHTX Health Care
- Exchange
- RFI Nasdaq
- FHTX Nasdaq
- Market Cap
- RFI 344.7M
- FHTX 517.9M
- IPO Year
- RFI N/A
- FHTX 2020
- Fundamental
- Price
- RFI $12.73
- FHTX $7.55
- Analyst Decision
- RFI
- FHTX Strong Buy
- Analyst Count
- RFI 0
- FHTX 5
- Target Price
- RFI N/A
- FHTX $16.00
- AVG Volume (30 Days)
- RFI 69.8K
- FHTX 135.3K
- Earning Date
- RFI 01-01-0001
- FHTX 11-04-2024
- Dividend Yield
- RFI 8.25%
- FHTX N/A
- EPS Growth
- RFI N/A
- FHTX N/A
- EPS
- RFI N/A
- FHTX N/A
- Revenue
- RFI N/A
- FHTX $35,185,000.00
- Revenue This Year
- RFI N/A
- FHTX N/A
- Revenue Next Year
- RFI N/A
- FHTX $15.40
- P/E Ratio
- RFI N/A
- FHTX N/A
- Revenue Growth
- RFI N/A
- FHTX 61.95
- 52 Week Low
- RFI $9.62
- FHTX $2.70
- 52 Week High
- RFI $12.52
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- RFI 44.70
- FHTX 45.26
- Support Level
- RFI $12.88
- FHTX $7.24
- Resistance Level
- RFI $13.14
- FHTX $8.35
- Average True Range (ATR)
- RFI 0.17
- FHTX 0.54
- MACD
- RFI -0.02
- FHTX -0.06
- Stochastic Oscillator
- RFI 21.74
- FHTX 43.20
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.